NCT04348383View on ClinicalTrials.gov

Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.

PHASE2CompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions

COVID19

Interventions

DRUG

Defibrotide

6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days

DRUG

Placebo

Placebo 250 cc every 6 hours for 7 or15 days

Trial Locations (6)

30120

Virgen de la Arrixaca University Clinical Hospital, Murcia

Unknown

Hospital General Universitario Santa Lucía, Cartagena

Hospital Clinico y Provincial de Barcelona, Barcelona

Hospital General Universitario Morales Meseguer, Murcia

Hospital General Universitario Reina Sofía, Murcia

Hospital Universitario Salamanca, Salamanca

All Listed Sponsors

lead

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

OTHER

NCT04348383 - Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19. | Biotech Hunter | Biotech Hunter